CARGO Therapeutics Future Growth
Future criteria checks 2/6
CARGO Therapeutics is forecast to grow earnings and revenue by 0.2% and 65.1% per annum respectively while EPS is expected to grow by 21% per annum.
Key information
0.2%
Earnings growth rate
21.0%
EPS growth rate
Biotechs earnings growth | 24.1% |
Revenue growth rate | 65.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 27 Jun 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 74 | -214 | -194 | -180 | 3 |
12/31/2025 | 1 | -233 | -199 | -195 | 5 |
12/31/2024 | N/A | -192 | -178 | -162 | 5 |
3/31/2024 | N/A | -121 | -107 | -97 | N/A |
12/31/2023 | N/A | -98 | -90 | -81 | N/A |
9/30/2023 | N/A | -80 | -71 | -64 | N/A |
6/30/2023 | N/A | -57 | -53 | -49 | N/A |
3/31/2023 | N/A | -46 | -42 | -39 | N/A |
12/31/2022 | N/A | -41 | -32 | -29 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRGX's revenue (65.1% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: CRGX's revenue (65.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CRGX's Return on Equity is forecast to be high in 3 years time